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MicroRNAs (miRNAs) are an evolutionarily conserved class of small 
noncoding RNAs that have recently gained status as important 
regulators of gene expression in diverse biological processes includ-
ing cellular proliferation, differentiation, and tumorigenesis (1). 
miRNAs are generally regarded as negative regulators of gene expres-
sion that inhibit translation and/or promote mRNA degradation by 
base pairing to complementary sequences within the 3′ untranslated 
region (3′ UTR) of protein-coding mRNA transcripts (2–4). miRNAs 
provide an additional posttranscriptional layer of spatial and tem-
poral control of developmental and homeostatic events by altering 
levels of critical regulators within complex genetic pathways (5–7).
The role of miRNAs in cardiac development and function has 
begun to be uncovered (8–10). In the developing mouse heart, 
overexpression of miR-1 caused defective ventricular myocyte pro-
liferation (11), while introduction of miR-1 into developing Xeno-
pus embryos also interfered with heart development (12). Targeted 
deletion of the mouse Mir1-2 gene, 1 of the 2 miR-1 genes expressed 
in skeletal and cardiac muscle, leads to lethality of approximately 
half of Mir1-2–null animals by weaning age and some suffer from 
abnormal cardiac morphogenesis and cardiac conduction defects 
(13). The global role of miRNA function in the heart has been 
addressed by conditionally inhibiting miRNA maturation in the 
murine heart and has revealed that miRNAs play an essential role 
during development (13, 14). In addition, miRNA expression pro-
filing studies demonstrate that the expression of specific miRNAs 
changes in diseased human hearts, pointing to the involvement of 
miRNAs in cardiomyopathies (15, 16).
A requirement for miR-208a in stress-dependent cardiac growth 
was recently reported (17). miR-208a is encoded by an intron of the 
α-cardiac muscle myosin heavy chain gene (Myh6) and is expressed 
specifically in the heart. Here, we report that miR-208a belongs to 
a miRNA family that includes miR-208b, which is encoded within 
the β-cardiac muscle myosin heavy chain gene (Myh7). We show 
that expression of miR-208a and miR-208b is developmentally 
and pathologically regulated in the heart. We found that the adult 
isoform miR-208a was sufficient to induce cardiac remodeling 
and regulate the expression of hypertrophy pathway components, 
including upregulation of βMHC. Conversely, genetic deletion of 
miR-208a resulted in decreased βMHC expression. We found that 
miR-208a and miR-208b shared nearly identical sequence iden-
tity and were able to repress the same target genes. Furthermore, 
miR-208a was sufficient to induce arrhythmias and miR-208a 
genetic deletion resulted in aberrant cardiac conduction. We also 
found miR-208a was required to maintain expression of cardiac 
transcription factors known to be important for development 
of the conduction system. Our results clearly demonstrate the 
pathological consequences of perturbing the expression of a sin-
gle miRNA in the heart and establish miR-208a as a regulator of 
hypertrophic growth and the cardiac conduction system.
Results
Cardiac myosin heavy chain genes encode intronic miRNAs. During 
development, the αMHC and βMHC isoforms are expressed in a 
developmental stage-specific manner (18). In mouse hearts, the 
slower isoform βMHC is fetal specific, while the faster isoform 
αMHC becomes the predominant isoform in the adult heart. In 
humans and other large mammals, βMHC expression continues 
into adulthood. However, increased βMHC expression is a com-
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mon feature of cardiac hypertrophy and heart failure in both 
mouse and human hearts (19, 20). An intron from each of the 
Myh6 and Myh7 genes host a conserved miRNA — miR-208a and 
miR-208b, respectively (Figure 1A). miR-208a expression was 
detected specifically in the adult mouse heart (Figure 1B) and 
could be detected at very low levels in the heart as early as E13.5 
(Figure 1C). The switch from fetal isoform βMHC to the adult 
isoform αMHC in the mouse occurs shortly after birth (Figure 
1D). We found that a similar switch from miR-208b to miR-208a 
expression also occurs, suggesting they are cotranscribed with 
their MHC host genes (Figure 1D). miR-208a and miR-208b 
are of similar sequence with identical seed regions (Figure 1A), 
which suggests they might be functionally redundant (21). How-
ever, miR-208b was not detectable in the adult heart, indicating 
Figure 1
Expression of miR-208a and miR-208b parallels the expression of their respective host genes Myh6 and Myh7. (A) miR-208a is encoded by 
intron 29 of the Myh6 gene, while miR-208b is encoded by intron 31 of the Myh7 gene. miR-208a and miR-208b are highly conserved and share 
similar sequence identity (indicated by asterisks). (B) Detection of mature and precursor miR-208a in adult mouse tissues. Sk. muscle, skeletal 
muscle; tRNA, transfer RNA. (C) Detection of mature and precursor miR-208a in E13.5, E16.5, and neonatal tissues using Northern blot analysis. 
(D) Top left: αMHC and βMHC transcripts were detected in E16.5, P0, P5, P10, and adult mouse hearts using RT-PCR. Bottom left: miR-208a 
and miR-208b expression was detected in the samples using Northern analysis. Right: Relative levels of miR-208a and miR-208b during heart 
development (E) Top left: αMHC and βMHC transcripts were detected using RT-PCR in isolated rat neonatal cardiomyocytes following treat-
ment with thyroid hormone (T3). Bottom left: miR-208a and miR-208b were detected using Northern analysis. Right: Quantitative analysis. Fold 
change is relative to no T3 treatment (which was set at 1). *P < 0.01, compared with no T3 treatment.
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that if miR-208a and miR-208b target the same mRNAs, they do 
so at different developmental stages.
Thyroid hormone signaling is a well-known regulator of αMHC 
and βMHC transcription (22). A surge of circulating thyroid hor-
mone that occurs shortly after birth represses βMHC expression 
and activates αMHC expression though negative and positive 
cis-acting elements within their respective promoters. We treated 
isolated rat cardiomyocytes with thyroid hormone and observed 
reduced βMHC/miR-208b expression while dramatically induc-
ing αMHC/miR-208a expression (Figure 1E). Together, those 
data suggest that the intronic miR-208 family and their MHC host 
genes are co-expressed and regulated by common transcriptional 
events and signaling pathways.
Cardiac overexpression of miR-208a is sufficient to induce cardiac 
hypertrophy. In an effort to understand the function of miR-208a 
in the adult heart, we overexpressed miR-208a specifically in the 
heart under the control of the α-myosin heavy chain (αMHC) 
promoter using a bigenic system. An advantage of this strategy is 
that miR-208a is overexpressed specifically at the same time and 
place it would normally be expressed. The overexpression strat-
egy consisted of a transgene encoding miR-208a downstream of 
a tetracycline-responsive promoter (TRE–miR-208a) and a second 
transgene encoding the tetracycline-controlled transactivator pro-
tein driven by the αMHC promoter (αMHC-tTA) (23). Using this 
system, we found that cardiac-specific overexpression of miR-208a 
did not cause embryonic lethality, and thus administration of tet-
Figure 2
Hearts of miR-208a Tg mice undergo hypertrophic growth. (A) Left: Northern blot analysis showing an approximately 4-fold increase of miR-208a 
expression in hearts of miR-208a Tg animals compared with control littermates. U6 served as loading control. Right: Quantitative analysis of 
fold change in miR-208a expression compared with control animals. *P < 0.001. (B) Gross morphology of miR-208a Tg hearts was enlarged 
compared with control hearts. Scale bar: 1 mm. (C) Heart weight to body weight ratios (Hw/Bw) of 4-month-old miR-208a Tg mice (n = 22) 
were significantly higher than controls (n = 19) (P < 7 × 10–7). (D) Macroscopic view of H&E-stained histological sections (upper, sagittal; lower, 
transverse) from control and miR-208a Tg hearts. Scale bars: 1 mm. (E) Sarcomeric structure of cardiomyocytes visualized by desmin staining 
of histological sections. Original magnification, ×200. (F) Histological sections were stained with wheat germ agglutinin–TRITC conjugate to 
determine cell size. Mean cardiomyocyte size of miR-208a Tg hearts (n = 930) was significantly larger than control cardiomyocytes (n = 926) 
(*P < 9 × 10–50). Original magnification, ×200. (G) Distribution of control and miR-208a Tg cardiomyocyte cell area measurements were com-
pared. (H) Representative M-mode echocardiographs from conscious control and miR-208a Tg mice. IVSTD, interventricular septal thickness in 
diastole; IVSTS, interventricular septal thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; 
LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension.
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racycline to delay transgene expression was unnecessary. Multiple 
founder TRE–miR-208a Tg lines were established. Primary analyses 
indicated that miR-208a was overexpressed at similar levels; there-
fore we combined results from the studies of different Tg lines. 
Throughout our studies, we compared heterozygous mice carrying 
the αMHC-tTA and TRE–miR-208a transgenes (referred to hereafter 
as “miR-208a Tg mice”) with mice heterozygous for αMHC-tTA 
(referred to hereafter as “control mice”).
Northern blot analysis showed miR-208a levels were approxi-
mately 4-fold higher in miR-208a Tg hearts compared with 
control hearts (Figure 2A). In situ hybridization using a DIG-
labeled miR-208a probe confirmed that miR-208a was uni-
formly overexpressed in most cardiomyocytes (Supplemental 
Figure 1; supplemental material available online with this arti-
cle; doi:10.1172/JCI36154DS1). The gross heart morphology of 
4-month-old miR-208a Tg hearts was dramatically larger relative 
to control littermates (Figure 2B). Accordingly, the heart weight 
to body weight ratios of miR-208a Tg animals were significantly 
higher than in control animals (Figure 2C). Histological section-
ing and H&E staining revealed the appearance of enlarged cham-
bers and thickened ventricular walls in the miR-208a Tg hearts, 
suggestive of hypertrophic growth (Figure 2D and Supplemental 
Figure 2). Analysis of desmin, an intermediate filament found 
near the sarcomeric Z line, revealed no changes in the integrity in 
the sarcomeric structure of miR-208a Tg cardiomyocytes (Figure 
2E). Quantitative measurement of miR-208a Tg cardiomyocytes 
revealed a 52% increase in cell size relative to controls (Figure 2F). 
The distribution of the cell size measurements from control and 
Tg cardiomyocytes clustered around distinct peaks, indicating that 
the hypertrophy in miR-208a Tg heart is fairly uniform (Figure 
2G). Together, these results indicate that miR-208a overexpression 
in the mouse heart induced hypertrophic growth.
Cardiac hypertrophy is the heart’s primary response to stress 
caused by pathological and physiological hemodynamic overload, 
abnormal hormonal signaling, and certain inherited disorders 
involving particular transcription factors and contractile proteins 
(19). Hypertrophic growth involves enhanced protein synthesis, 
increased sarcomeric density, and increased cardiomyocyte size 
that culminates into structural remodeling of the heart. Although 
cardiac hypertrophy is considered an adaptive mechanism to 
sustain cardiac output, prolonged pathological hypertrophy has 
adverse consequences associated with heart failure and sudden 
death (24). Analysis of cardiac function by echocardiography on 
3-month-old animals revealed that miR-208a Tg hearts displayed 
thickening of the ventricular walls (anterior wall in diastole and 
systole, posterior wall in diastole), an increase in left ventricular 
diameter (left ventricular diameter in diastole and systole), and 
deterioration in cardiac function, as indicated by decreased frac-
tional shortening (Figure 2H and Table 1). We also measured car-
diac function in 7-month-old animals and obtained similar results 
(Supplemental Table 1).
A molecular hallmark of cardiac hypertrophy is the 
upregulation of βMHC and the cardiac hormone atrial natri-
uretic factor (ANF) in the adult heart (19, 20). Consistent with 
hypertrophic growth, we observed increased expression of 
βMHC transcripts and proteins, by real-time PCR and Western 
blot analyses, respectively, in miR-208a Tg hearts (Figure 3, A 
and B). Unexpectedly, no significant changes in ANF transcript 
levels were detected (Figure 3A).
Changes in the expression levels of specific miRNAs have been 
reported in diseased human hearts and in animal models of heart 
disease, pointing to their potential roles in cardiomyopathies 
(15, 16, 25–27). Since βMHC expression is a hallmark of cardiac 
hypertrophy and because βMHC and miR-208b appear to be 
co-regulated, we surmised that miR-208b expression would also 
increase during cardiac hypertrophy. Using a mouse model of car-
diac hypertrophy in which the aorta was surgically constricted to 
produce chronic pressure overload, we indeed found miR-208b 
expression induced during hypertrophic growth (Figure 3C). 
Furthermore, miR-208b expression was found induced in adult 
miR-208a Tg hearts (Figure 3D). We also analyzed the expression 
of miRNAs whose expression levels have been reported altered in 
cardiac hypertrophy. While previous studies reported decreased 
miR-1, miR-133, and miR-29a expression levels and increased 
miR-125b expression levels in cardiac hypertrophy (15, 16, 25–27), 
in our study the expression levels of those miRNAs were not sig-
nificantly affected in miR-208a Tg hearts relative to control hearts 
(Figure 3D). Together, those data demonstrate that miR-208a 
induced hypertrophic growth without affecting all aspects of the 
hypertrophic growth response pathway.
We also determined whether the effects of miR-208a overexpres-
sion on hypertrophy could be recapitulated in vitro using isolated 
rat neonatal cardiomyocytes. Cardiomyocytes were transduced with 
miR-208a–expressing or control adenoviruses, then immunostained 
for α-actinin or βMHC (Figure 3E). Consistent with the role of 
miR-208a in the induction of cardiac hypertrophy in vivo, over-
expression of miR-208a in isolated cardiomyocytes increased 
cell size and βMHC expression but did not significantly affect 
ANF levels (Figure 3, E–H). Conversely, knockdown of miR-208a 
by introducing chemically modified oligonucleotides (2′O-meth-
yl modified) into isolated cardiomyocytes resulted in decreased 
βMHC expression, but the size of cardiomyocytes and ANF 
expression were not affected (Figure 3, E–H). Taken together, these 
results using in vivo and in vitro strategies suggest that miR-208a 
influences a subset of genes important in cell growth rather than 
activating a broader hypertrophic pathway.
Spatial distribution of βMHC in miR-208a Tg hearts is focal. Increased 
βMHC expression during cardiac hypertrophy is a well-estab-
Table 1
Echocardiography of dimensions and function of miR-208a 
Tg mice
Parameter	 Control	 miR-208a	Tg
BW (g) 25.0 ± 1.14 26.1 ± 1.24
LV mass (mg) 107 ± 1.45 163 ± 6.33A
LV mass/BW (mg/g) 3.94 ± 0.09 6.04 ± 0.24A
HR (bpm) 713 ± 8.9 697 ± 12.3
IVSTD (mm) 0.93 ± 0.01 1.11 ± 0.04A
IVSTS (mm) 1.55 ± 0.02 1.73 ± 0.04B
PWTD (mm) 0.85 ± 0.03 1.00 ± 0.03B
PWTS (mm) 1.60 ± 0.03 1.48 ± 0.06
LVEDD (mm) 3.2 ± 0.03 3.5 ± 0.09A
LVESD (mm) 1.48 ± 0.03 2.0 ± 0.07A
FS% 51.7 ± 0.77 41.2 ± 1.16A
Transthoracic echocardiography on unanesthetized mice. HR, heart 
rate. Left ventricular mass index was calculated as (external left ventricu-
lar diameter in diastole3 – LVEDD3) × 1.055. Fractional shortening (FS) 
was calculated as (LVEDD – LVESD) / LVEDD. AP < 0.0001; BP < 0.001, 
compared with control. Data are mean ± SEM. n = 10/group.
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Figure 3
miR-208a overexpression induces hypertrophic gene expression. (A) Transcripts for αMHC, βMHC, and ANF were detected by real-time 
PCR in 4-month-old hearts from control and miR-208a Tg mice (n = 5 per genotype). Data are the mean fold change in expression ± SEM. 
*P < 0.01. (B) Left: Western blot analysis of total MHC and βMHC protein levels in adult control and miR-208a Tg hearts. Right: Quantitative 
analysis of fold change in protein levels. *P < 0.01. (C) Top left: RT-PCR was used to detect αMHC, βMHC, and ANF transcripts in wild-type 
hearts following 3 weeks thoracic aortic banding (TAB) or in surgical sham hearts, which were used as controls. Bottom left: miR-208a and 
miR-208b were detected by Northern blot analysis. U6 served as a loading control. Right: Quantitative analysis of fold change in expression of 
mRNAs and miRNAs. *P < 0.01. (D) Northern blot and quantitative analysis of expression of miRNAs using hearts from control and miR-208a 
Tg mice. (E–H) Isolated rat neonatal cardiomyocytes were transduced with miR-208a and control adenoviruses (Ad-208 and Ad-Cntl, respec-
tively) or transfected with oligonucleotides antisense to miR-208a or control oligonucleotides (2′Ome-208a and 2′Ome-Cntl, respectively). 
(E) Cardiomyocytes were stained for α-actinin or βMHC proteins. Original magnification, ×200. (F) Fold change in mean cell area ± SEM of 
α-actinin–immunostained cardiomyocytes were treated with adenoviruses or oligonucleotides (n = 100 cells/condition; **P < 4 × 10–12). (G) Fold 
change in mean fluorescent intensity ± SEM of βMHC-immunostained cardiomyocytes treated with adenoviruses or oligonucleotides (n = 100 
cells/condition; #P < 3 × 10–7). (H) Cardiomyocytes were treated with adenoviruses or antisense 2′O-methyl oligonucleotides and were scored 
for ANF staining (n ≈ 425 cells/condition).
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lished phenomenon and is thought to contribute to the overall 
poor functioning of the hypertrophic heart (28–30). To better 
assess the effects of miR-208a on the expression of βMHC, we 
employed a mouse strain harboring a βMHC indicator allele, in 
which the yellow fluorescent protein (YFP) sequence is fused to 
the Myh7 gene (31). We bred this allele into the miR-208a Tg line. 
The YFP-βMHC was highly expressed in neonatal cardiomyo-
cytes, but was essentially unexpressed in adult hearts (ref. 31, Fig-
ure 4A, and data not shown). We observed dramatically increased 
YFP-βMHC protein levels in the miR-208a Tg hearts (Figure 4A 
and Supplemental Figure 3). However, YFP-βMHC expression 
did not increase in all cardiomyocytes of miR-208a Tg hearts. 
Rather it was intensely upregulated only in areas associated with 
interstitial fibrosis (Figure 4, B and C, and Supplemental Figure 
3). This observation is consistent with an earlier report in which 
the distribution of βMHC was analyzed and found correlated 
with fibrosis in an established mouse model of cardiac hyper-
trophy (31). Inhibition of thyroid hormone synthesis by propyl-
thiouracil (PTU) results in hypothyroidism and increases βMHC 
expression due to loss of thyroid hormone–mediated repression 
at the βMHC promoter (22). PTU treatment of adult miR-208a 
Tg mice resulted in uniform upregulation of YFP-βMHC expres-
sion throughout the myocardium after 4 weeks, indicating that 
expression of the βMHC indicator allele recapitulates βMHC 
expression (Supplemental Figure 4). Thus, even though in situ 
hybridization analyses for mature miR-208a revealed uniform 
overexpression in miR-208a Tg cardiomyocytes (Supplemental 
Figure 1), βMHC re-expression occurred only in a subset of car-
diomyocytes associated with fibrosis.
We next tested whether βMHC re-expression correlated with the 
miR-208a–induced hypertrophic growth of individual cardiomyo-
cytes. To do this, we compared the cell areas of miR-208a Tg;YFP-
βMHC cardiomyocytes with the areas of control YFP-βMHC 
cardiomyocytes lacking the miR-208a transgene. No association 
between the state of YFP-βMHC expression and cell area increase 
was observed (Figure 4D). Thus, cardiomyocytes from miR-208a 
Tg hearts were significantly larger than the cardiomyocytes from 
control hearts independently of whether they were positive or 
negative for YFP-βMHC expression (Figure 4D). Taken together, 
these observations demonstrate that βMHC expression is not an 
obligate component of miR-208a–induced hypertrophic growth 
and that overexpression of miR-208a alone is sufficient to induce 
hypertrophic growth in cardiomyocytes even when they show no 
re-activation of Myh7 gene expression.
Targeted deletion of miR-208a alters cardiac gene expression. Having 
demonstrated that miR-208a is sufficient for hypertrophic growth, 
we sought to examine miR-208a function using a loss-of-function 
approach in miR-208a knockout mice. We replaced the genomic 
sequence encoding miR-208a by homologous recombination with 
a neomycin selection cassette flanked by loxP sites (Figure 5, A and 
B). The selection cassette was subsequently excised by Cre-medi-
ated recombination, leaving only a small footprint of exogenous 
Figure 4
Distribution of YFP-βMHC fusion protein in miR-208a Tg hearts. (A) Confocal fluorescent images of coronal sections from control and miR-208a 
Tg hearts. Overlapping images were stitched together using ImageJ. Original magnification, ×40. (B) Papillary muscle from control and miR-208a 
Tg hearts imaged for YFP-βMHC (green) expression and wheat germ agglutinin–TRITC staining (red). Original magnification, ×200. (C) Repre-
sentative fluorescent images of YFP-βMHC expression (green) in an area of interstitial fibrosis (red) in miR-208a Tg hearts. Original magnifica-
tion, ×200. (D) Mean cell area ± SEM of cardiomyocytes from miR-208a Tg; YFP-βMHC and control; YFP-βMHC hearts. Cells measured for area 
were also scored for presence or absence of YFP-βMHC expression (n = 100/genotype; *P < 0.001).
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DNA in place of miR-208a (Figure 5C). Since miR-208a is located 
within an intron of the Myh6 gene, we confirmed that the splic-
ing pattern of the αMHC transcript was unaffected by the mutant 
miR-208a allele (Supplemental Figure 5).
The progeny that resulted from mating Mir208a+/– mice were via-
ble and born at an expected Mendelian ratio (Figure 5D). miR-208a 
expression was halved in Mir208a+/– hearts compared with the wild-
type hearts and was undetectable in Mir208a–/– hearts (Figure 5E 
and Supplemental Figure 1). Hearts of 12- to 16-week-old Mir208a–/– 
mice did not display any gross morphological abnormalities and 
appeared normal compared with wild-type littermates (data not 
shown). Furthermore, no differences in heart weight to body 
weight ratios were observed when comparing Mir208a–/– and wild-
type mice (Figure 5F). Those results are consistent with a recent 
report in which miR-208a was shown to not be required for nor-
mal heart development and function (17).
Figure 5
Expression of βMHC is decreased in Mir208a–/– hearts. (A) Strategy to delete miR-208a from intron 31 of the Myh6 gene by homologous recom-
bination. The miR-208a coding sequence (green box) was replaced by a neomycin selection cassette flanked by loxP sites (red triangles). The 
selection cassette was excised from the germline by mating with mice that ubiquitously expressed Cre recombinase, thus creating a mutant allele 
that contained a single loxP sequence in place of miR-208a. Genotyping PCR primers and 5′ probes are indicated. NdeI, restriction enzyme 
site; P1, primer binding site 1. (B) The occurrence of the intended recombination event in mouse ES cells was confirmed by PCR and Southern 
blot analyses. (C) The increased length of the mutant allele was the basis for a PCR-based genotyping strategy. (D) Genotypes of progeny from 
mating miR-208a mice were born at a Mendelian ratio (n = 128). (E) Northern blot analysis for miR-208a expression in hearts from wild-type 
(Mir208a+/+), Mir208a+/–, and Mir208a–/– mice. *P < 0.01. (F) Heart weight to body weight ratios of 4-month-old wild-type and Mir208a–/– mice 
(n = 25/genotype). (G) Transcripts for αMHC, βMHC, and ANF were detected by real-time PCR in hearts from wild-type and Mir208a–/– mice 
(n = 5/genotype). Values are presented as the fold change in mean expression ± SEM. *P < 0.01. (H) Western blot analysis of total MHC and 
βMHC protein levels in hearts from wild-type and Mir208a–/– mice. **P < 0.05. (I) Northern blot analysis of miRNA expression using hearts from 
wild-type, Mir208a+/–, and Mir208a–/– mice.
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Consistent with the role of miR-208a in the regulation of cardiac 
hypertrophic growth and βMHC expression, we found that βMHC 
transcript and protein levels were significantly reduced, while 
αMHC and ANF transcript levels were unchanged in Mir208a–/– 
hearts (Figure 5, G and H). This result complements the elevation 
of βMHC transcript and protein levels observed in miR-208a Tg 
hearts (Figure 3, A and B). Together, those genetic data provide 
convincing evidence that miR-208a is important for the regulation 
of βMHC expression. We also examined the expression of miRNAs 
that were downregulated in miR-208a Tg hearts (Figure 3D). Sur-
prisingly, we found that the expression of those miRNAs appeared 
unchanged in Mir208a–/– hearts, indicating that their expression is 
not dependent upon miR-208a (Figure 5I).
miR-208a and miR-208b repress the expression of thyroid hormone–associ-
ated protein 1 and myostatin. Utilizing the web-based TargetscanHu-
man database (http://www.targetscan.org/), we selected several pre-
dicted miR-208a target genes for experimental scrutiny (32, 33). A 
target site located in the 3′ UTR of thyroid hormone–associated pro-
Figure 6
miR-208a and miR-208b repress the expression of Thrap1 and myostatin. (A) Sequence alignment between miR-208a and candidate bind-
ing sites in the 3′ UTR of Thrap1 and myostatin. (B) Northern blot analysis demonstrated that miR-208a, miR-208b, and miR-124 expression 
plasmids produced mature miRNAs when transfected into 293T cells. Total RNA from mouse brain and neonatal and adult hearts was included 
as a control. U6 served as a loading control. (C) 293T cells were transfected with a luciferase reporter designed to detect miR-208a expression 
(208a sensor), along with the indicated miRNA expression plasmids. A Thrap1 3′ UTR (luc-Thrap1) and a mutated Thrap1 3′ UTR (luc-Thrap1 
mutant) were also tested. Values are mean luciferase activity ± SD relative to the luciferase activity of reporters cotransfected with an empty 
expression plasmid. The dotted line indicates the basal level of luciferase activity in control (i.e., the luciferase vector alone). (D) A luciferase 
reporter with duplicated Thrap1 binding sites (luc-Thrap1 4×) was cotransfected with miRNA expression plasmids and luciferase activity deter-
mined. (E) A luciferase reporter with 4 repeats of the putative myostatin binding site was cotransfected with miRNA expression plasmids and 
luciferase activity determined. (F) Western blot analysis for Thrap1 and myostatin protein levels in hearts from 4-month-old miR-208a Tg versus 
control animals and Mir208a–/– versus wild-type animals. GAPDH served as a loading control. *P < 0.05.
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tein 1 (Thrap1) is among the most heavily weighted target sites for 
miR-208a and was chosen for study since thyroid hormone signaling 
is a known repressor of βMHC transcription (34, 35). Upon closer 
inspection of the Thrap1 3′ UTR, we identified a second conserved 
miR-208a target site located approximately 60 bp downstream of 
the first target site (Figure 6A and Supplemental Figure 6).
In addition, myostatin is also predicted to be a miR-208a regula-
tory target, with a single miR-208a target site in its 3′ UTR (Fig-
ure 6A and Supplemental Figure 6). Myostatin stood out as an 
interesting candidate, given its role as a repressor of hypertrophic 
growth in skeletal muscle (36, 37). Myostatin is also expressed in 
cardiac muscle, although to a much lesser degree than it is found 
in skeletal muscle, and genetic inactivation of myostatin in mice 
has been recently linked to cardiac hypertrophy (38–41).
As a first step toward determining which genes are targeted by 
miR-208a and miR-208b, we cloned genomic fragments encoding 
miR-208a, miR-208b, and miR-124 into plasmids for overexpression 
in cultured cells (Figure 6B). We hypothesized that similar sequences 
and identical seed regions shared by miR-208a and miR-208b would 
enable them to repress similar sets of genes, while miR-124 is a brain-
specific miRNA and served as a control miRNA for specificity.
Thrap1 is part of the thyroid hormone nuclear receptor complex 
and can positively and negatively influence transcription (42, 43). 
Thus we reasoned that repression of Thrap1 by miR-208a might 
account for the increased βMHC expression in miR-208a Tg hearts 
(Figure 3, A and B). In agreement with this notion, cotransfection 
of a luciferase gene with the Thrap1 3′ UTR cloned immediately 
downstream (luc-Thrap1) and the miR-208a expression plasmid 
in cultured cells resulted in repressed luciferase activity (Figure 
6C). Expression of miR-124 with luc-Thrap1 had no such effect 
upon luciferase activity, which indicated that miR-208a repres-
sion of luc-Thrap1 was specific. To further confirm this specific-
ity, we mutated the candidate miR-208a target sites (luc-Thrap1 
mutant), which resulted in the complete loss of miR-208a–medi-
ated repression (Figure 6C and Supplemental Figure 6). As we 
predicted from the sequence similarity shared by miR-208a and 
miR-208b, we found that miR-208b also repressed the luc-Thrap1 
luciferase activity (Figure 6C). As another demonstration of 
miR-208a and miR-208b targeting of Thrap1 and to test wheth-
er increasing the number of target sites would also increase the 
degree of repression, we duplicated the Thrap1 target sites down-
stream of the luciferase gene (luc-Thrap1 4×). Indeed, increasing 
the target site number resulted in a pronounced decrease in lucif-
erase activity, indicating that target site number is an important 
factor in miRNA-mediated repression (Figure 6D).
In order to directly test whether miR-208a could repress the 
expression of myostatin, we constructed 4 repeats of the myostatin 
target sequence downstream of a luciferase gene (luc-myostatin 4×) 
and cotransfected with miRNA expression 
plasmids. Transfection of either miR-208a 
or miR-208b plasmids repressed luc-myo-
statin 4× luciferase activity (Figure 6E). 
Transfection of the miR-124 plasmid caused 
no decrease in luc-myostatin 4× luciferase 
activity and confirmed that miR-208a and 
miR-208b specifically target the myostatin 
3′ UTR (Figure 6E).
To determine whether Thrap1 and myo-
statin were regulated in vivo by miR-208a, 
we tested whether their expression was 
altered in our miR-208a gain- and loss-of-function mouse mod-
els. The transcript levels of Thrap1 and myostatin appeared 
unchanged in the miR-208a Tg and Mir208a–/– hearts (Supple-
mental Figure 6). However, the protein levels of Thrap1 and myo-
statin were repressed in miR-208a Tg hearts compared with con-
trol hearts (Figure 6F). Conversely, the protein levels of Thrap1 
and myostatin were elevated in Mir208a–/– hearts compared with 
hearts from wild-type littermates (Figure 6F). Taken together, 
these observations demonstrated that Thrap1 and myostatin are 
bona fide miR-208a targets.
miR-208a is a regulator of the cardiac conduction system. To determine 
whether miR-208a overexpression disturbed cardiac conduction, 
we recorded surface ECGs of 4-month-old miR-208a Tg and con-
trol mice. Analysis of the ECG recordings showed significantly pro-
longed PR intervals in miR-208a Tg mice compared with control 
mice (Table 2 and Figure 7A). The PR interval is the period of time 
between the onset of atrial depolarization and the onset of ventric-
ular depolarization; abnormal prolongation of the PR interval is 
clinically considered first-degree AV block. No significant differ-
ences were detected in other ECG parameters, such as QRS, QT, 
or QTc intervals (Table 2). We also recorded and analyzed surface 
ECGs from 1- and 6-month-old animals and obtained similar 
results (Supplemental Table 2). Interestingly, approximately 30% of 
the miR-208a Tg mice also had second-degree AV blocks, in which 
one or more of the electrical impulses from the atria failed to pass 
through the AV node to the ventricles, causing failures in ventricu-
lar contraction (Figure 7B). Second-degree AV blocks appeared on 
the ECG tracings as P waves (atrial depolarizations) without subse-
quent occurrence of QRS complexes (ventricular depolarizations) 
(Figure 7B). Taken together, the development of progressive heart 
blocks in miR-208a Tg mice demonstrates that miR-208a overex-
pression results in cardiac conduction abnormalities and suggests 
that miR-208a regulates cardiac conduction system components.
We and others have found that genetic deletion of miR-208a does 
not affect viability or cause gross morphological heart defects but 
is required for stress-dependent heart growth (Figure 5 and ref. 17). 
To determine whether miR-208a is also required for proper heart 
electrophysiology during normal conditions, we monitored heart 
function of 4-month-old Mir208a–/– and wild-type littermates by 
surface ECGs and found that miR-208a is necessary for proper car-
diac conduction. The ECGs of approximately 80% of the Mir208a–/– 
mice lacked P waves preceding QRS complexes, suggesting that 
Mir208a–/– mice suffer atrial fibrillation (Figure 7, C and D). 
Consistent with a defect in atrial conduction, the PR intervals in 
Mir208a–/– mice were significantly prolonged compared with wild-
type animals (Table 2). Collectively, the ECG analyses of miR-208a 
Tg and Mir208a–/– mice demonstrate that miR-208a is an impor-
tant component of the cardiac conduction system.
Table 2
Summary of 4-month surface ECG findings
Mouse	 HR	(bpm)	 PR	(ms)	 QRS	(ms)	 QT	(ms)	 QTc	(ms)
Control (n = 11) 500 ± 24 38 ± 1 9 ± 0 48 ± 2 43 ± 1
miR-208a Tg (n = 16) 460 ± 17 46 ± 2A 9 ± 1 50 ± 2 43 ± 1
Mir208a+/+ (n = 8) 491 ± 22 37 ± 1 9 ± 0 53 ± 1 48 ± 1
Mir208a–/– (n = 10) 503 ± 22 49 ± 1B 11 ± 1 50 ± 2 54 ± 2
AP < 0.01; BP < 0.001, compared with control.
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Normal conduction is mediated by the orderly propagation of 
electrical impulses from one cardiomyocyte to the next. The con-
nexin proteins are gap junction proteins required for this propaga-
tion, and their altered expression is a common feature in a variety 
of chronic human heart diseases associated with increased risk of 
arrhythmias and sudden death (44–47). Studies of mouse mod-
els have demonstrated that deficiencies in either connexin 43 
(Cx43) or Cx40 result in cardiac conduction defects (48). Cx43 is 
expressed in cardiomyocytes throughout the heart, whereas Cx40 
expression is restricted to the atria and the specialized cardiomyo-
cytes that constitute the His bundle and Purkinje fibers (48). Previ-
ous studies suggested that abnormal connexin protein expression 
might account for, at least in part, the cardiac conduction defects 
induced by altered miR-208a levels (49–51).
We therefore evaluated the expression of Cx43 and Cx40 in hearts 
from 4-month-old miR-208a Tg and Mir208a–/– mice. Transcript 
analysis by real-time PCR did not reveal any readily apparent changes 
to Cx43 transcript levels in either miR-208a Tg or Mir208a–/– hearts 
(Figure 8, A and B). Though Cx40 transcript levels were not affected 
in miR-208a Tg hearts (Figure 8C), they were markedly decreased in 
Mir208a–/– hearts compared with wild-type (Figure 8D), indicating 
that miR-208a is required for Cx40 expression. Furthermore, West-
ern blot and immunohistological analyses of hearts from Mir208a–/– 
mice showed decreased Cx40 protein levels compared with wild-type 
hearts (Figure 8E and Supplemental Figure 7). Consistent with the 
Mir208a–/– phenotype, mice lacking Cx40 suffer cardiac conduction 
abnormalities, including first-degree AV block (49).
miR-208a maintains expression of cardiac transcription factors. The tran-
scription factor homeodomain-only protein (Hop) is highly expressed 
within the adult murine conduction system, and Hop genetic dele-
tion results in postnatal conduction defects accompanied by a loss 
of Cx40 expression (52). Therefore, we speculated that the decreased 
Cx40 expression observed in Mir208a–/– hearts might partially stem 
from reduced Hop expression. We evaluated Hop transcripts levels 
by real-time PCR using hearts from 4-month-old animals and found 
Hop expression to be abolished in Mir208a–/– mice (Figure 8F). 
Accordingly, Hop protein was also undetectable in Mir208a–/– hearts 
(Figure 8G). Our observations indicate that Hop is not directly regu-
lated by miR-208a, but instead that miR-208a targets a transcrip-
tion factor associated with Hop and/or required for Hop expression. 
GATA4 and Nkx2.5 are transcriptional cofactors expressed within 
the cardiac conduction system of the adult heart and coordinately 
transactivate the expression of serum response factor–dependent 
promoters, including Cx40 and Hop (53, 54). Interestingly, the 3′ 
UTR of Gata4 mRNA contained a predicted miR-208a target site 
(Supplemental Figure 8), and so we reasoned that the miR-208a 
gain- and loss-of-function phenotypes might partially result from 
irregular GATA4 protein expression (55). In order to directly test 
whether miR-208a could repress the expression of GATA4, we con-
structed 4 repeats of the GATA4 target sequence downstream of a 
luciferase gene (luc-GATA4) and cotransfected with miRNA expres-
sion plasmids. Cotransfection of miR-208a with the luc-GATA4 
reporter repressed luciferase activity (Figure 8H). However, cotrans-
fection of control miR-124 caused no decrease in luciferase activity, 
demonstrating that miR-208a specifically targeted the 3′ UTR of 
GATA4 (Figure 8H). To determine whether GATA4 is regulated in 
vivo by miR-208a, we tested whether GATA4 expression was altered 
in the Mir208a–/– hearts. Indeed, GATA4 protein levels were elevated 
in Mir208–/– hearts compared with hearts from wild-type littermates 
(Figure 8I). Consistent with posttranscriptional regulation, the 
GATA4 transcript levels were unchanged in Mir208a–/– hearts (data 
not shown). Taken together, these observations demonstrate that 
miR-208a directly targets the cardiac transcription factor GATA4.
Discussion
In this study, we investigated the function and molecular mecha-
nisms of the miR-208 family in adult heart physiology. Our find-
ings, which we believe are novel, include the following: (a) miR-208a 
Figure 7
miR-208a is sufficient to induce arrhythmias and is required for proper cardiac conduction. (A) Representative waveforms in lead I indicate the 
location and relative duration of PR intervals in 4-month-old miR-208a Tg and control mice. (B) Representative ECGs in lead I of 4-month-old 
miR-208a Tg and control mice. Asterisks mark missing QRS complexes and indicate occurrences of second-degree atrioventricular block. (C) 
Representative waveforms in lead I from Mir208a–/– and wild-type mice. Asterisk indicates the normal position of the P wave, which was absent in 
Mir208a–/– mice. (D) Representative ECGs in lead I from 4-month-old Mir208a–/– and wild-type mice. Asterisks mark the presence of the P wave.
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and miR-208b are members of miR-208 family and are differentially 
expressed during heart development and heart pathology, parallel-
ing the expression of their respective host genes, αMHC and βMHC. 
(b) Cardiac overexpression of miR-208a is sufficient to induce hyper-
trophy. (c) miR-208a–induced βMHC expression is restricted to a 
subset of cardiomyocytes associated with fibrosis. (d) βMHC expres-
sion is dramatically decreased in Mir208a–/– mouse hearts. (e) Both 
miR-208a and miR-208b target Thrap1 and myostatin, 2 important 
negative regulators of muscle growth and hypertrophy. (f) miR-208a 
is necessary for normal cardiac conduction. miR-208a gain- and loss-
of-function are associated with arrhythmias. Together, the results of 
our study provide critical functional and mechanistic insights into 
how miRNAs participate in the regulatory cascade to modulate car-
diac remodeling and normal physiology.
The βMHC and αMHC isoforms are major contractile proteins 
of cardiomyocytes and differ primarily in their ability to convert 
ATP to mechanical work at different rates, thus their relative pro-
tein expression ratio affects contractility of the cardiac sarcomeres 
(56, 57). Increased expression of βMHC is a common feature of 
cardiac hypertrophy and heart failure that reduces contractile per-
formance and is thought to be a maladaptive response (28–30). 
The shift towards βMHC is reversible under particular conditions 
that are associated with improved cardiac performance, including 
the regression of hypertrophy and human patients that respond 
favorably to β blocker therapy (58–62). Furthermore, mutations 
in the Myh7 gene are commonly associated with hypertrophic 
cardiomyopathies (63). Therapies that inhibit the maladaptive 
features of hypertrophy might be useful in improving the func-
tion of the diseased heart (20). However, the molecular events that 
induce hypertrophy and govern hypertrophic gene expression are 
not well defined. More specifically, it is not fully understood how 
βMHC is regulated during cardiac remodeling and how its reacti-
vation contributes to functional maladaptation. Our experimental 
results demonstrate that miR-208a is sufficient to induce cardiac 
hypertrophy in Tg hearts. Interestingly, the hypertrophic growth 
induced by miR-208a is only accompanied by increased βMHC 
expression in a subset of hypertrophied cardiomyocytes. It will be 
important to perform time course experiments in the future to 
determine the temporal regulation of βMHC by miR-208a.
In contrast, deletion of miR-208a resulted in decreased βMHC 
expression in the adult heart, providing genetic evidence that miR-
208a is required for βMHC expression. Our results are consistent 
with a prior report showing that loss of miR-208a blunted stress-
induced cardiac hypertrophy and βMHC reactivation (17). Striking-
ly, upregulated βMHC expression in miR-208a Tg hearts is tightly 
associated with regional fibrosis, similar to what we previously 
Figure 8
miR-208a is required for proper expression of gap junction protein connexin 40 and cardiac transcription factors GATA4 and Hop. (A and B) 
Transcripts for Cx43 were detected by real-time PCR in hearts from (A) miR-208a Tg and control mice (n = 5/genotype) and (B) wild-type and 
Mir208a–/– mice (n = 5/genotype). (C and D) Transcripts for Cx40 were detected in hearts from (C) miR-208a Tg and control mice (n = 5 each gen-
otype) and (D) wild-type and Mir208a–/– mice (n = 5/genotype). Values in A–D are presented as the fold change in expression ± SEM. *P < 0.01. 
(E) Western blotting for Cx40 proteins using hearts from 4-month-old wild-type and Mir208a–/– mice. β-Tubulin served as a loading control. (F) 
Transcripts for Hop were detected by real-time PCR in hearts from wild-type and Mir208a–/– mice (n = 5/genotype). (G) Western blotting for Hop 
proteins using hearts from 4-month-old wild-type and Mir208a–/– mice. (H) 293T cells were transfected with a luciferase reporter designed to 
detect miR-208a expression and with miRNA expression plasmids, and luciferase activity was determined. A luciferase reporter with 4 repeats 
of the putative miR-208a binding site was also cotransfected with miRNA expression plasmids and luciferase activity determined. Values are 
mean luciferase activity ± SD relative to the luciferase activity of reporters cotransfected with empty expression plasmid. (I) Western blotting for 
GATA4 proteins using hearts from 4-month-old wild-type and Mir208a–/– mice. **P < 0.05.
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found in renin-induced hypertrophy (31). The strong correlation 
of re-expression of βMHC and fibrosis development may explain 
why such reactivation of fetal genes is associated with a maladap-
tive phenotype. Further studies to understand how induced βMHC 
expression is associated with fibrosis will likely shed light on the 
biology of cardiac hypertrophy and heart failure.
Our findings demonstrate that miR-208a posttranscriptionally 
represses the expression of Thrap1, a component of the thyroid 
hormone nuclear receptor complex. Thyroid hormone signaling 
has long been an established regulator of cardiac myosin heavy 
chain isoform expression: a surge of circulating thyroid hormone 
that occurs after birth transcriptionally represses βMHC expres-
sion while activating αMHC expression (34, 35). Studies have also 
shown that excessive administration of thyroid hormone leads 
to the development of cardiac hypertrophy, but the molecular 
mechanism was elusive (64–67). Our findings, in which increas-
ing the level of miR-208a in Tg hearts reduced Thrap1 levels and 
induced hypertrophic growth, provide a link between the action 
of miR-208a and thyroid hormone in cardiac hypertrophy. We 
find that miR-208a posttranscriptionally represses Thrap1, which 
is consistent with a previous report (17). We extended our previ-
ous observations by uncovering an additional conserved miR-208 
family binding site within the Thrap1 3′ UTR. Furthermore, we 
demonstrated that both miR-208a and miR-208b target those 
sites. In addition, we found that miR-208a and miR-208b target 
myostatin, a negative regulator of hypertrophic growth. The find-
ings that both miR-208a and miR-208b repress Thrap1 and myo-
statin to a comparable level further suggest that miR-208 family 
members may target similar genes in vivo. A key disparity between 
our findings and that of an earlier report is the ability of miR-208a 
to induce cardiac hypertrophy. We believe the degree of miR-208a 
transgene expression accounts for this difference; we report higher 
miR-208a transgene expression levels, which indicate that surpass-
ing a particular threshold of miR-208 family expression is impor-
tant for facilitating hypertrophic growth.
In addition to the important role for miR-208a in cardiac hyper-
trophy, our studies also identify miR-208a as a key regulatory mol-
ecule necessary for proper cardiac conduction. Our experiments 
demonstrate that miR-208a is sufficient to induce cardiac arrhyth-
mias, while miR-208a is also required to maintain proper cardiac 
conduction. Our results further indicate that miR-208a is required 
to maintain the expression of Cx40, whose misexpression is associ-
ated with cardiac arrhythmias (49). We also find that GATA4 and 
Hop are upregulated and downregulated, respectively, in Mir208a–/– 
hearts. While GATA4 is directly targeted by miR-208a, Hop is likely 
indirectly regulated by miR-208a. We found that both transcript 
and protein levels of Hop were lower in Mir208a–/– hearts compared 
with wild-type hearts. Thus, altering miR-208a expression affects 
the delicate regulation of potent cardiac transcription factors. 
However, the cardiac conduction defects revealed in miR-208a Tg 
and Mir208a–/– mice did not phenocopy Cx40 and Hop loss-of-
function animal models. This is perhaps not entirely surprising, 
since miRNAs are proposed to fine-tune the expression of targeted 
mRNAs that produce protein products important for a particular 
tissue and to reduce transcriptional noise by helping to turn over 
misexpressed mRNAs (68–73). By direct or indirect effects, a single 
miRNA may fine-tune the expression of thousands of genes (73). In 
this sense, the precise molecular mechanisms underlying miR-208a– 
mediated regulation of cardiac conduction system components 
have yet to be defined. Identification of the cardiac transcription 
factors whose expressions are posttranscriptionally fine-tuned by 
miR-208a will likely be the key to understanding miR-208a func-
tion. Additional studies are needed to test and further define this 
intriguing possibility.
Our present finding that miR-208a is required to maintain Hop 
expression may also help to explain the blunted hypertrophic 
growth response of Mir208a–/– hearts (17). Unlike most homeobox 
transcription factors, Hop does not bind DNA directly. Instead, Hop 
recruits histone deacetylase 2 and inhibits the transcriptional activi-
ty of serum response factor in cardiomyocytes (74–76). Interestingly, 
Hop overexpression was reported to induce cardiac hypertrophy and 
is proposed to inhibit an antihypertrophy gene program in the adult 
heart (76). A potential explanation for the inability of Mir208a–/– 
hearts to undergo hypertrophic growth may stem from the lack of 
Hop protein available to repress this antihypertrophy gene program. 
It will be important to understand how miR-208a regulates the 
expression of Hop and connexin proteins in the future.
Cardiac function and remodeling are intimately linked to the 
regulation of complex genetic pathways, and much effort has 
been expended in attempts to understand the molecular mech-
anisms underlying these pathways, with the ultimate goal of 
improving the prognosis of heart patients (77). Much of our cur-
rent understanding of how cardiac gene expression is controlled 
is at the level of transcriptional regulation, in which transcription 
factors associate with their regulatory DNA elements (enhancer/
promoter sequences) to activate gene expression (78). The regula-
tion of cardiac gene expression is complex, with individual cardiac 
genes controlled by multiple independent enhancers that direct 
very restricted expression patterns in the heart. miRNAs have 
reshaped our view of how cardiac gene expression is regulated, 
increasing this complexity even further, by adding another layer 
of regulation at the posttranscriptional level. The results reported 
in this study clearly established a role for miR-208a in repressing 
antihypertrophy genes as part of the genetic program needed for 
hypertrophic growth. Although the arrhythmogenesis induced by 
perturbing miR-208a levels warrants much caution, we anticipate 
that inhibition of miR-208a may be a viable therapeutic strategy 
to repress βMHC expression and might remove some of the mal-
adaptive features of hypertrophy.
Methods
Generation of miR-208a Tg mice. All procedures were approved by and 
performed in accordance with the University of North Carolina 
Institutional Animal Care and Use Committee. A genomic fragment 
encoding the miR-208a precursor and flanking region was ampli-
fied by PCR using mouse genomic DNA as a template (miR-208a 
forward, GTCATCTAGAAAGCTTGATGCAGGAAAGAGCTTT-
GG, reverse, TGACAGATCTCAGCTGACATCCTCTAGGCT-
GGGGTT). This fragment was cloned into the pUHG10-3 tetra-
cycline responsive vector plasmid at the XbaI site. A 2-kb fragment 
containing TRE, miR-208a precursor, and SV40 poly signal was 
excised by XhoI/AseI digestion and purified. The TRE–miR-208a 
gene was injected into the pronuclei of C57BL/6 × C3H hybrid 
embryos and implanted into pseudo-pregnant recipient females by 
the University of North Carolina Animal Models Core. Five TRE–
miR-208 founder mice were established and crossed with C57BL/6 
mice and expanded. Separate strains derived from 2 founders were 
maintained by mating animals heterozygous for TRE–miR-208a 
or αMHC-tTA, which expresses heart-specific tTA controlled by 
the heart-specific αMHC promoter (provided by Glenn I. Fishman, 
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New York University, New York, New York, USA) (23). Single-Tg 
animals genotyped αMHC-tTA (referred to as “control mice”) 
were compared with double-Tg littermates genotyped αMHC-tTA/
TRE–miR-208 (referred to as “miR-208a Tg mice”).
Generation of Mir208a–/– mice. The miR-208a targeting vector was 
generated by digesting a 4.5-kb fragment (5′ arm) with NheI/XhoI 
and ligated upstream of a positive-selection neomycin cassette 
flanked by loxP sites. A 1.8-kb fragment (3′ arm) was digested with 
PmeI/NotI and ligated downstream of the neomycin cassette and 
upstream of a negative-selection thymidine kinase cassette. Tar-
geted ES cells were identified by PCR and Southern blot analyses 
and used for blastocyst injection by the University of North Caro-
lina Animal Models Core. The resulting chimeric mice were bred 
to C57BL/6 mice to obtain germline transmission of the floxed 
allele. Subsequently, the neomycin cassette was excised by breed-
ing with β-actin–Cre mice (79).
Pressure overload–induced hypertrophy model. Male C57BL/6 mice 
(6–8 weeks old) were subjected to pressure overload by thoracic 
aortic banding (25). Mice were sacrificed after 3 weeks of banding, 
and hearts were harvested for RNA extraction.
Hypothyroidism model. Thyroid hormone deficiency was induced 
by feeding adult mice for 4 weeks with iodine-free chow supple-
mented with 0.15% PTU (catalog TD 97061; Harlan Teklad).
Histologic analysis of miR-208a Tg mice. Histologic analyses of heart 
tissues were performed according to standard procedures. Samples 
were stained with H&E for routine examination and agglutinin-
wheat germ-TRITC conjugate to identify sarcolemmal membranes 
so that myofiber diameter could be quantified. Antibodies against 
desmin (catalog ab17156; Abcam) were used to visualize sarco-
meric structure. Images were collected on an epifluorescent micro-
scope (Eclipse E800; Nikon). Quantification of cardiomyocyte 
surface area was performed using ImageJ software on fluorescent 
micrographs from 4 hearts per genotype, using about 225 cells per 
heart across multiple sections.
Transthoracic echocardiography. Unanesthetized mice were 
restrained on a temperature-controlled mouse board (Indus Instru-
ments), and echocardiography was performed on miR-208a Tg 
and control mice using a Vevo 660 ultrasound system (Visual Son-
ics) equipped with a 30-MHz transducer. An echocardiographer 
blind to animal genotype captured 2-dimensional parasternal long 
axis views of the left ventricle. From this view, an M-mode cursor 
was positioned perpendicular to the interventricular septum and 
the posterior wall of the left ventricle at the level of the papillary 
muscles. The following measurements were obtained for systole 
and diastole using 4 cardiac cycles averaged: interventricular septal 
thickness, left ventricular posterior wall thickness, left ventricular 
internal diameter, heart rate, and fractional shortening.
Surface electrocardiograms. Mice were anesthetized with 1%–2% 
isoflurane in 700 ml O2/min via a face mask (following induction 
chamber containing 5% isoflurane). Rectal temperature was mon-
itored and maintained at 37°C using a heat pad and heat lamp. 
ECGs using multiple leads were recorded for about 3 minutes at 2 
MHz from needle electrodes inserted subcutaneously into the each 
limb. Recordings were analyzed using the ECG module of LabChart 
5 software (AD Instruments), and QTc intervals were calculated 
using a formula developed for analyzing murine data (80).
Northern blot analysis and RT-PCR. RNA analyses by miRNA North-
ern blot, semi-quantitative RT-PCR, and quantitative RT-PCR 
were essentially performed as described (12, 31, 81). Quantitative 
RT-PCR was performed on 5 mouse hearts per genotype tested.
Immunoblotting and immunostaining. Immunoblotting and 
immunostaining were essentially performed as previously 
described (12) using antibodies to βMHC (catalog M8421; 
Sigma-Aldrich), MHC (antibody MF20; University of Iowa Devel-
opmental Studies Hybridoma Bank), myostatin (catalog AB3239; 
Chemicon, Millipore), Thrap1 (a gift from Robert G. Roeder, 
Rockefeller University, New York, New York, USA), Cx40 (cata-
log 36-4900; Invitrogen), Cx43 (catalog C8093; Sigma-Aldrich), 
GATA4 (catalog sc-1237; Santa Cruz Biotechnology Inc.), Hop (a 
gift from Eric Olson, University of Texas Southwestern Medical 
Center at Dallas, Dallas, Texas, USA), β-tubulin (catalog C4585; 
Sigma-Aldrich), and GAPDH (catalog MAB374; Chemicon, Mil-
lipore). Western blotting was performed on least 4 animals per 
genotype and repeated independently.
miRNA in situ hybridization. miRNA in situ hybridization was per-
formed essentially as previously described (82) using locked nucle-
ic acid (LNA) probes complementary to mouse mature miR-208 
(product 39102-05; Exiqon) or scrambled control sequence (prod-
uct 99004-05; Exiqon) with 3′ digoxigenin conjugates. LNA probes 
were hybridized to mouse heart cryosections and washed at 37°C.
Cultured cardiomyocyte experiments. Preparation of neonatal rat 
cardiomyocytes was done as previously described (81). Cardio-
myocytes were treated with triiodo-L-thyronine (Sigma-Aldrich) 
essentially as previously described (83). Antisense 2′O-methyl–
modified oligonucleotides were transfected using Lipofectamine 
(Invitrogen). Cardiomyocytes were transduced with miR-208a or 
GFP-expressing adenoviruses at MOI 10. Immunostaining per-
formed using antibodies against α-actinin (catalog A5044; Sigma-
Aldrich), βMHC (catalog M8421; Sigma-Aldrich), and ANF (cata-
log sc-20158; Santa Cruz Biotechnology Inc.). For fluorescence 
intensity analysis, individual cardiomyocytes (at least 100 cell 
bodies per condition) were measured on a 0–255 grayscale using 
ImageJ software. The intensity of immunostaining was reported as 
the fold change in mean gray value ± SEM. Cardiomyocyte experi-
ments were independently repeated at least 3 times.
Confocal analysis of hearts from miR-208a Tg; YFP-βMHC mice. The 
miR-208a Tg line was bred with the YFP-βMHC reporter line. The 
YFP-βMHC mice harbor a YFP-βMHC fusion allele that allows 
precise and accurate assessment of βMHC expression in adult 
hearts (31). Hearts from heterozygous triple-Tg mice expressing 
YFP-βMHC, tTA, and miR-208a (YFP-βMHC; αMHC-tTA; TRE–
miR-208a mice) were compared with heterozygous double-Tg lit-
termates expressing YFP-βMHC and tTA (YFP-βMHC; αMHC-tTA 
mice). Paraformaldehyde-fixed hearts were sectioned with a vibro-
tome at 150-μm thicknesses. Individual sections were treated with 
sodium borohydride (1 mg/ml in PBS) for 30 minutes to reduce fix-
ative-induced fluorescence. Sections were stained with Alexa Fluor 
633–conjugated agglutinin wheat germ and analyzed with a FV500 
confocal microscope (Olympus). Morphometric analyses were con-
ducted on coronal sections using individual cell areas from the left 
ventricular free wall that were traced with ImageJ software (31).
Cloning and expression of miR-208a, miR-208b, and miR-124. Genom-
ic fragments of miR-208a, miR-208b, and miR-124 precursors were 
amplified by PCR using mouse genomic DNA as a template. PCR 
products were cloned into pcDNA(+)3.1 vector (Invitrogen), and 
miRNA expression was confirmed by Northern blot analysis of 
transfected 293T cells (Fugene6; Roche).
Luciferase reporter assays. A modified pGL3-control vector 
(pGL3cm) for 3′ UTR–luciferase reporter assays was described 
previously (12). The TargetScanHuman database (http://www.
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targetscan.org/) was used to identify predicted miR-208 bind-
ing sites. A 575-bp fragment of the Thrap1 3′ UTR was ampli-
fied from a mouse cDNA library and cloned downstream of the 
luciferase gene to create the luc-Thrap1 construct. Duplication of 
the 2 Thrap1 target sites was accomplished by PCR subcloning a 
portion of the Thrap1 3′ UTR directly into the initial Thrap1 con-
struct to create luc-Thrap1 4×. Seed region mutations were gener-
ated by site-directed mutagenesis (Supplemental Figure 6). The 
luc-myostatin 4× and luc-GATA4 4× reporter constructs were gen-
erated by annealing oligonucleotides encoding 2 mouse miR-208 
target sites separated by 10 bp and cloning them in tandem down-
stream of the luciferase gene. To confirm miRNA expression in the 
reporter assays, we generated miRNA sensor constructs consisting 
of perfectly complementary sequences to miR-208a or miR-124 
directly downstream of the luciferase gene. Reporter assays were 
conducted using 293T cells in triplicate at least 3 times in 24-well 
plates. Transfections were performed with 50 ng of reporter and 
50, 100, or 150 ng of miRNA plasmids (Fugene6; Roche). A CMV-
lacZ reporter was used as an internal control to normalize for 
transfection efficiencies, and the total amount of DNA per well 
was kept constant by adding the corresponding amount of empty 
expression vector.
Statistics. Values are reported as means ± SEM unless indicated 
otherwise. The 2-tailed Mann-Whitney U test was used for compar-
ing 2 means (Prism; GraphPad). Values of P < 0.05 were considered 
statistically significant.
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